Accessibility Help | Sitemap | Contact Us | Customer Support CALL 1-800-275-4524
United States Change Country
Careers | Investor Relations | News & Media | Events | KCI Recycling | About KCI
Home  |  Conditions  |  Products  |  Clinical Evidence  |  Education and Training  |  For Patients  |  Customer Support  |  Suppliers
You are here: Home > About KCI > News & Media > Media Inquiries
Print

News & Media

These press releases are intended as reference information for U.S. investors and journalists. The information contained in each press release was current at the time of issuance, and KCI assumes no responsibility for updating the information to reflect subsequent developments.

Top Stories

KCI, Leader in Advanced Wound Care Solutions New Study Comparing ABThera™ to BVPT, Published in the Annals of Surgery, Demonstrated Reduced 90-Day Mortality

KCI, Leader in Advanced Wound Care Solutions Acelity L.P. Inc. Reports Fourth Quarter and Full Year Financial Results for 2014

  • Fourth quarter revenue grew 6.5% compared to the prior-year period, on a constant currency basis
  • Fourth quarter 2014 Adjusted EBITDAfrom continuing operations1 grew 5.4% compared to the prior-year period, on a constant currency basis
  • Fourth quarter loss from continuing operations was $30.9 million compared to $52.0 million for the prioryear period

Headlines

Displaying 21 to 30 of 157 News Items
August 26th 2013
ABThera™ Open Abdomen Negative Pressure Therapy System Study Published in World Journal of Surgery

Significantly Improved Patient Outcomes Using ABThera™ Negative Pressure Therapy System in Open Abdomen Surgery

August 12th 2013
KCI Introduces New V.A.C. VeraFlo™ Large Dressing

Taking Away the Large Burden of Wound Healing

July 30th 2013
KCI to Acquire Systagenix

Strategic Transaction Strengthens KCI Leadership Position in Global Wound Care Market While Adding Diversification

Enhances Access to $3.4 Billion Advanced Wound Care Market, Leveraging KCI’s Well-Established Customer Relationships, Brand and Commercial Scale

Complementary Product Portfolio Will Advance Provision of Best-in-Class Solutions to Healthcare Professionals and Patients
 

July 9th 2013
KCI Launches Novel Tool to Simplify Epidermal Harvesting

CelluTome™ Epidermal Harvesting System makes harvesting and subsequent grafting of epidermis accessible to more clinicians and patients

June 20th 2013
KCI Initiates Negative Pressure Wound Therapy with Instillation Randomized, Controlled Prospective Study

Study to Compare Traditional Negative Pressure Wound Therapy to V.A.C. VeraFlo™ Instillation Therapy, using the V.A.C.Ulta™ Negative Pressure Wound Therapy System

May 22nd 2013
KCI Launches Prevena™ Peel & Place™ Dressing with V.A.C.® Therapy Connector

Benefits of surgical incision management now available to more patients

May 16th 2013
New Study Reports Key Findings for the ABThera™ Open Abdomen Negative Pressure Therapy System

Observational Study Showed Significantly Improved Patient Outcomes When the ABThera™ Negative Pressure Therapy System was Used in Open Abdomen Surgery

May 7th 2013
Independent Study Showed Decrease in Operating Room Visits for Patients with Infected Wounds using Adjunctive V.A.C. VeraFlo™ Therapy

Trend to Reduction in Hospital Stay vs. Traditional Negative Pressure Wound Therapy

April 29th 2013
KCI Announces Global Rollout of Novel Skin Graft Harvesting Tool

US Wound Care Physicians Introduced to CelluTome™ Epidermal Harvesting System

Displaying 21 to 30 of 157 News Items

  • KCI Express
  • Share on Facebook.com
  • Share on Twitter
  • Visit our YouTube page

Important Message for Patients

Terms of Use | Privacy Policy | Contact Us | News Feed


Copyright © 1998 - 2013 KCI Licensing, Inc. All Rights Reserved.    DSL# 09-03-193
The information included in this Web site has been prepared for and is intended for viewing exclusively within the United States of America. This Web site contains information about products which may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please consult individual country sites for approved uses and any applicable restrictions.